Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients
- 1 June 1999
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 13 (9) , 1045-1049
- https://doi.org/10.1097/00002030-199906180-00007
Abstract
To assess the impact of long-term virus suppression on the peripheral blood CD4 T cells integrated and total HIV-1 DNA loads in patients receiving highly active antiretroviral therapy (HAART). A total of 10 HIV-1-infected patients receiving a triple combination therapy (two nucleoside analogues and one protease inhibitor) were longitudinally studied to compare integrated and total HIV-1 DNA loads. HIV-1 DNA quantification was performed using a quantitative nested polymerase chain reaction (PCR) on genomic peripheral blood mononuclear cell (PBMC) DNA obtained at baseline and at 48 weeks of HAART. All the study patients showed an early and sustained decrease in plasma HIV-1 RNA to below the limit of detection (200 copies/ml). Concordant with the plasma viral decline, a significant increase in the CD4 T cell count was observed (P=0.007). A statistically significant fivefold decrease in total HIV-1 DNA was detected after 48 weeks of HAART (P=0.005). However, no statistically significant change was noted after the therapy when the integrated HIV-1 DNA copy number was compared (P=0.333). Taken together, these results suggest that in the patients analysed the integrated HIV-1 DNA does not decay rapidly after HAART. Within the study cohort the total amount of PBMC HIV-1 DNA decreased drastically after 48 weeks of HAART. Nevertheless, the integrated HIV-1 DNA did not significantly decay during this period. Although the data presented here are limited by the number of patients analysed, our findings suggest that 48 weeks of HAART does not significantly reduce the integrated HIV-1 proviral DNA load in the latently infected CD4 T cell reservoir.Keywords
This publication has 19 references indexed in Scilit:
- Early establishment of a pool of latently infected, resting CD4 + T cells during primary HIV-1 infectionProceedings of the National Academy of Sciences, 1998
- Toward HIV Eradication or Remission: The Tasks AheadScience, 1998
- Exploring How to Get at--and Eradicate--Hidden HIVScience, 1998
- Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapyProceedings of the National Academy of Sciences, 1997
- Recovery of Replication-Competent HIV Despite Prolonged Suppression of Plasma ViremiaScience, 1997
- Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral TherapyScience, 1997
- Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failureProceedings of the National Academy of Sciences, 1997
- Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral TherapyNew England Journal of Medicine, 1997
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation TimeScience, 1996